Hospital Board Member Eleanor Beaumont Demanded Her Daughter-in-Law End Her Comatose Son's Life — But Dr. Evelyn Reed Knew the Truth
The downtown public library was a sanctuary of hushed whispers and rustling pages. Sunlight streamed through tall arched windows, illuminating dust motes dancing in the air. I found Isabella exactly where she said she’d be, tucked away amidst towering shelves of historical texts.
She looked just as I remembered her: sharp, observant, her eyes holding a keen intelligence. She wore simple, understated clothes, a stark contrast to Eleanor’s usual designer attire. She looked up as I approached, a small, knowing smile on her lips.
“Dr. Reed,” she greeted softly, extending a hand. Her grip was firm and confident. “Thank you for coming.”
“Thank you for reaching out, Isabella,” I replied, sitting opposite her at a large, worn oak table. “I appreciate the discretion.”
She nodded, her gaze sweeping the room cautiously before settling back on me. “My mother has a habit of monitoring those she sees as threats. And right now, that’s you.”
Her blunt assessment was unsettling but unsurprising. Eleanor’s reach was a constant, invisible pressure.
“Your email mentioned your father’s health records,” I began, cutting straight to the point. “And discrepancies in his will.”
Isabella leaned forward, her voice dropping to an even lower conspiratorial tone. “My father was a generous man, but also meticulous. His personal finances were always perfectly ordered. Until the last few years.”
She pulled out a small, worn leather-bound notebook and a few printouts. These weren’t official bank statements, but detailed personal ledgers, meticulously kept. Her father’s handwriting, neat and precise, filled the pages.
“After he died, settling his estate was… complicated,” she explained, pushing one of the printouts toward me. “Eleanor handled most of it, of course. But I had copies of some of his personal ledgers.”
I looked at the printout. It was a summary of Charles Beaumont’s personal medical fund, specifically designated for his long-term health needs. The numbers were staggering, far more than anyone would expect for standard medical care, even for a prolonged illness.
“This is an enormous fund,” I observed. “He must have been very ill to warrant such provisions.”
Isabella nodded. “He was. Much more than Eleanor ever let on. But that’s not the discrepancy.”
She pointed to a series of transactions marked in red pen, notations that looked like Isabella’s own additions. They showed massive withdrawals, totaling nearly a million dollars (USD) over a period of two years.
“These withdrawals,” she explained, her finger tracing the entries, “started shortly after Thomas turned sixteen. And they weren’t for my father’s treatment.”
My eyes widened. “Not for his treatment? Then what were they for?”
Isabella shook her head. “That’s what I could never figure out. The money went to a shell corporation, a holding company with no clear public-facing business. Eleanor always said it was a ‘secret investment’ my father made, something for the family’s future, but it never generated any returns.”
A million dollars, siphoned away into a ghost fund. And the timing – “shortly after Thomas turned sixteen” – was deeply unsettling. This tied directly into my own suspicions about Thomas’s health history, his “issues” from adolescence.
“Did Thomas have any specific medical issues around that time?” I asked, my voice hushed. “Anything that required… extensive treatment?”
Isabella’s face clouded with a memory. “He was very sick for a while. Doctors couldn’t figure it out. Eleanor kept everything very quiet, very private. Said it was ‘teenage malaise’ and a ‘sensitive constitution.’ But I remember Thomas losing weight, being exhausted, having strange tremors.”
The tremors. The exhaustion. The “teenage malaise.” It all echoed the symptoms of atypical progressive atrophy. And Eleanor’s public dismissal of Thomas’s early suffering mirrored her treatment of Charles’s illness. The pattern was horrifyingly consistent.
“Eleanor was unusually secretive about Thomas’s health during that period,” Isabella continued. “She barely let anyone visit him. It was all cloistered, hush-hush. And she was spending a lot of time on the phone, making urgent calls, almost frantic.”
The image of Eleanor, frantic and secretive, didn’t align with her usual composed demeanor. This suggested a crisis, something she desperately wanted to hide. And she was using Charles’s medical fund to do it.
“This massive withdrawal,” I said, pointing to the ledger. “It lines up with Thomas’s ‘teenage issues.’ It doesn’t feel like a coincidence.”
“No,” Isabella agreed, her jaw tight. “It feels like my mother was buying something. Or covering something up. The timing is too perfect.”
She pulled another printout from her notebook, this one a more official-looking document, though still clearly a personal copy. It was a transfer of funds from the shell corporation to an overseas account, listed under a medical research firm.
“This is where the money eventually ended up,” Isabella explained, pushing it across the table. “An experimental drug research firm, based in Switzerland. They folded a few years later, after some scandal I could never quite get details on.”
An experimental drug research firm. A million dollars of Charles’s medical fund, diverted to a secretive offshore company, during Thomas’s mysterious illness, and the firm later collapsed under scandal. The pieces were starting to slot into place, forming a dark and disturbing picture.
“This isn’t just about covering up a family disease,” I murmured, my mind racing. “This is about a financial investment. A desperate one.”
“My mother is very protective of her investments,” Isabella confirmed, a bitter edge to her voice. “And her reputation. If she put a million dollars into something, she expects a return. Or at least to protect the original capital.”
This new layer, the financial motive, added a chilling dimension to Eleanor’s actions. She wasn’t just hiding a genetic secret; she was trying to salvage a failed, expensive, and possibly unethical venture.
The realization hit me like a punch to the gut. The procedure Eleanor was now so aggressively pushing for Thomas – the “cutting-edge” experimental treatment – suddenly clicked into focus. What if it wasn’t just a desperate attempt to cure Thomas, but a desperate attempt to recoup her lost investment?
“Isabella,” I said, my voice barely above a whisper. “The experimental procedure Eleanor is pushing for Thomas now… what if it’s connected to this firm? To this lost investment?”
Isabella’s eyes widened, reflecting my own dawning horror. Her previous suspicions had been purely financial, but now, the medical implications, coupled with her mother’s ruthlessness, opened up a truly terrifying possibility.
“You think she’s trying to salvage something?” Isabella asked, her voice tight with disbelief. “Using Thomas? After all this time?”
“It would explain her extreme aggression,” I replied, the pieces falling together with sickening clarity. “Her insistence on this specific, risky procedure. Her willingness to cut off his other care, to forge documents. She needs this to happen.”
The cruel, personal dimension of Eleanor’s actions intensified. She wasn’t just denying a truth; she was actively, dangerously leveraging her own son’s life to recover losses from a past, failed scheme. It was the ultimate betrayal.
“This is beyond monstrous,” Isabella whispered, running a hand through her hair. Her face was pale with disgust and a dawning understanding. “To use her own son like that. To put him through a revived, failed experiment.”
I gripped her arm, a silent plea for her continued help. “We need to find out everything about that Swiss firm. What they were researching. What the scandal was.”
Isabella nodded, her eyes hardening with resolve. The initial shock was giving way to a fierce determination. This wasn’t just about financial discrepancies anymore; it was about saving Thomas and exposing a lifetime of deceit.
“I have contacts,” she stated, gathering her papers. “People who are very good at digging up old dirt on offshore companies. Especially ones that involve medical research and a lot of money.”
The library still hummed around us, oblivious to the quiet storm we had just unleashed. But for Isabella and me, the silence felt charged with a new, terrifying purpose. We were united by a common enemy and a shared, desperate need for the truth. Eleanor’s ghost fund was no longer just a financial anomaly; it was a direct threat to Thomas’s life.
More Stories
+ There are no comments
Add yours